Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKP-1052 versus immediate-release terbutaline and placebo in stable type 1 diabetes mellitus
2010-022513-26Phase 2Completed
- Sponsor
- Skyepharma
- Start
- Dec 2010
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of SKP-1052, terbutaline and Placebo-COD Research Private Ltd in diabetes mellitus type 1 (T1D) (4 arms), sponsored by Skyepharma. Primary endpoint: Mean nadir blood glucose concentration. Started Dec 2010; status: completed.
02
Drugs
SKP-1052terbutalinePlacebo-COD Research Private Ltd
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2010-022513-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022513-26.